The first week of September saw family office capital support biotech innovators, aerospace suppliers and AI-driven drug discovery platforms. From strategic acquisitions to late-stage venture rounds, these investments underscore the sectoral breadth of family office capital and its growing influence in high-growth industries.
Sept. 3 – B&S Aircraft Alloys, a New York distributor of high-performance alloys for aerospace, defense and energy, was acquired by Dallas Opportunity Partners, a Texas family office investment group. The acquisition strengthens its portfolio in critical infrastructure sectors. (PR Newswire)
Sept. 3 – MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, closed a €55M Series B; participants included ATHOS, the single-family office of German billionaire Thomas Strüngmann. (Business Wire)
Sept. 4 – Enveda Biosciences, an AI-powered drug discovery company, secured $150 million in Series D funding to advance immune and obesity therapies into clinical trials. The round was led by Premji Invest (Indian businessman and philanthropist Azim Premji’s family office), alongside Kinnevik, Dimension and Lux Capital. (BusinessWire)